Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Vaccinex (VCNX) has issued an update.
Vaccinex, Inc. has announced the completion of the final patient visit in its SIGNAL-AD Phase 1b/2 study, evaluating pepinemab as a treatment for Alzheimer’s disease. This milestone marks a significant step forward in the development of the drug, capturing the interest of investors and stakeholders in the potential impact on Alzheimer’s treatment and Vaccinex’s future prospects.
For a thorough assessment of VCNX stock, go to TipRanks’ Stock Analysis page.